Anthera Pharmaceuticals Company Description

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs.

It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.

The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Anthera Pharmaceuticals, Inc.

Country	United States
Founded	2004
Industry	Biotechnology
Sector	Healthcare
Employees	21
CEO	John Thompson

Contact Details

Address: The Pennzoil Building Houston, Delaware 77002 United States
Phone	410 350 1839
Website	anthera.com

Stock Details

Ticker Symbol	ANTH
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US03674U3005
SIC Code	2836

Key Executives

Name	Position
Paul F. Truex M.B.A.	Executive Chairman
May Liu CPA	Senior Vice President of Finance and Administration and Principal Accounting Officer
Dr. Paul Adams Ph.D.	Senior Vice President of Global Regulatory Affairs and Compliance
Joshua Caldwell	Chief Liquidating Officer